

IN THE CLAIMS:

Please amend claims 3, 4, 5, 6, 7, 10, 12, and 13, as follows:

1. (Original) The use of a VEGF receptor gene or gene product for producing a preparation for preventing and treating conditions and diseases, in particular arteriosclerosis and ischemia, which are accompanied by overshooting neointimal proliferation, for promoting neovascularization and for supportive therapy in connection with shunts, for the local treatment of areas of damage to the blood vessel endothelium, in particular before, during or after angioplasty, and for restenosis prophylaxis.
2. (Original) The use as claimed in claim 1, characterized in that the preparation comprises a KDR-encoding sequence as the VEGF receptor gene and/or KDR (kinase insert domain-containing receptor) as the gene product.
3. (Currently Amended) The use as claimed in claim 1-~~or~~2, characterized in that the gene/sequence is present in an expression vector, preferably functionally assigned to a promoter.
4. (Currently Amended) The use as claimed in claim 1-~~or~~2, characterized in that the gene product is assigned to a transport unit, in particular in combination with a transport protein.
5. (Currently Amended) The use as claimed in ~~one of claims 1 to 4~~ claim 1, characterized in that the preparation additionally comprises means for modulating the synthesis, expression and/or stability of a VEGF-receptor-encoding mRNA.

6. (Currently Amended) The use as claimed in ~~one of claims 1 to 5~~ claim 1, characterized in that the preparation comprises further pharmaceutically tolerated additives and auxiliary substances and/or further pharmaceutical active compounds.
7. (Currently Amended) The use as claimed in ~~one of claims 1 to 6~~ claim 1, characterized in that the preparation is provided within a device for supplying it or on, at or in an implant, in particular a stent.
8. (Original) The use of a VEGF receptor gene or gene product for preventing and treating conditions and diseases, in particular arteriosclerosis and ischemia, which are accompanied by overshooting neointimal proliferation, for promoting neovascularization and for supportive therapy in connection with shunts, for local treatment of areas of damage to the blood vessel endothelium, in particular before, during or after angioplasty, and for restenosis prophylaxis.
9. (Original) The use of a VEGF receptor gene or gene product as claimed in claim 8 for therapy in balloon catheter-assisted dilatation in connection with constricted coronary blood vessels.
10. (Currently Amended) The use as claimed in claim 8 ~~or 9~~, wherein a VEGF receptor gene is used in an expression vector.
11. (Original) The use as claimed in claim 10, wherein transient expression of the VEGF receptor is induced.
12. (Currently Amended) The use as claimed in ~~one of the preceding claims~~ claim 1, wherein the VEGF receptor gene or gene product is present in a form in which it is encapsulated by nanoparticles, microparticles or

microspheres, in the form of a controlled release system or in the form of a solution.

13. (Currently Amended) The use as claimed in ~~one of the preceding claims~~ claim 1, wherein the VEGF receptor gene or gene product is impregnated in or on a stent or stored in an infiltration balloon catheter or a sideport balloon catheter.
14. (Original) A device, in particular stent or catheter, for use within blood vessels, comprising an effective quantity of a VEGF receptor gene or a VEGF receptor, or functional moieties thereof having the same biological effect.